Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

École Polytechnique de Montréal

$36,000.00

Translational research for cancer therapy based on medical nanorobotics

EF 2017-18

Résumé
Although the large majority of cancers are localized (85%), delivery systems still rely on systematically circulating vectors based primarily on physical characteristics and biochemical principles alone which result to only a small fraction of the total administered dose reaching the active tumor cells. Indeed, systemic delivery combined with the limitation of therapeutic vectors to diffuse deeper in tumor tissues and the inability to target all tumor activecells are known to be major obstacles to achieve optimal treatment outcomes for localized cancers. As such, Paul Ehrlichs magic bullet concept has stimulated research for therapeutic agents with the capability to go straight to their intended targets. The magic bullet concept is still considered the ultimate approach to maximize the therapeutic effects of a given drug molecule without affecting non-target tissues. But the reality is that there has never been a drug or drug delivery system that goes straight to the target in the body, and no approach has provided anything better than a few percent of the total administered dose reaching the intended target site. Over the last 15 years, we have been the pioneers and the leaders in a new paradigm in drug delivery where nanotechnology has been combined with principles of robotics to develop the medical nanorobotic technologiesenabling new navigable therapeutic agentsto gostraight to the site of treatment while sparing healthy tissues, hence providinga newapproachthat could be considered as a modernversion ofthe ""magic bullet"" for localized cancers. By doing so, we expect that the therapeutic effectswill be increased exponentially for a given therapeutic agent while minimizing the level of toxicityfor the patients, resulting in less hospital stays, potential savings in health cares, and a better quality of life for the patientsexperiencing more efficient therapeutic effectswithminimum risk of metastasis. With the active participation of clinicians, translational research efforts will be conducted and interventional procedures based on our unique medical nanorobotic technologies will be developed to providesolutions and cost effective approaches that better respond to unmet clinical needs, adding to the tool box of clinicians while providing more options to treat cancer.
Programme
Discovery Grants Program - Individual
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2017-06910
Name nom
Martel, Sylvain
Department département
Génie informatique et génie logiciel - Génie informatique et génie logiciel
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
5
Application title
Translational research for cancer therapy based on medical nanorobotics
Keyword
NSERC
Application summary
Although the large majority of cancers are localized (85%), delivery systems still rely on systematically circulating vectors based primarily on physical characteristics and biochemical principles alone which result to only a small fraction of the total administered dose reaching the active tumor cells. Indeed, systemic delivery combined with the limitation of therapeutic vectors to diffuse deeper in tumor tissues and the inability to target all tumor activecells are known to be major obstacles to achieve optimal treatment outcomes for localized cancers. As such, Paul Ehrlichs magic bullet concept has stimulated research for therapeutic agents with the capability to go straight to their intended targets. The magic bullet concept is still considered the ultimate approach to maximize the therapeutic effects of a given drug molecule without affecting non-target tissues. But the reality is that there has never been a drug or drug delivery system that goes straight to the target in the body, and no approach has provided anything better than a few percent of the total administered dose reaching the intended target site. Over the last 15 years, we have been the pioneers and the leaders in a new paradigm in drug delivery where nanotechnology has been combined with principles of robotics to develop the medical nanorobotic technologiesenabling new navigable therapeutic agentsto gostraight to the site of treatment while sparing healthy tissues, hence providinga newapproachthat could be considered as a modernversion ofthe ""magic bullet"" for localized cancers. By doing so, we expect that the therapeutic effectswill be increased exponentially for a given therapeutic agent while minimizing the level of toxicityfor the patients, resulting in less hospital stays, potential savings in health cares, and a better quality of life for the patientsexperiencing more efficient therapeutic effectswithminimum risk of metastasis. With the active participation of clinicians, translational research efforts will be conducted and interventional procedures based on our unique medical nanorobotic technologies will be developed to providesolutions and cost effective approaches that better respond to unmet clinical needs, adding to the tool box of clinicians while providing more options to treat cancer.